Skip to main content

Advertisement

SpringerLink
Log in

Cisplatin-based chemoradiotherapy trumps cetuximab-based bioradiotherapy in p16/HPV-positive oropharyngeal cancers

  • Letter to Editor
  • Published:
European Archives of Oto-Rhino-Laryngology Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 27 May 2019

The Original Article was published on 18 March 2019

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Suton P, Skelin M, Rakusic Z, Dokuzovic S, Luksic I (2019) Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE. Eur Arch Oto-Rhino-Laryngol. https://doi.org/10.1007/s00405-019-05387-8

    Article  Google Scholar 

  2. Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. http://www.handbook.cochrane.org. Accessed 21 Mar 2019

  3. Riaz N, Sherman E, Koutcher L, Shapiro L, Katabi N, Zhang Z et al (2016) Concurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neck. Am J Clin Oncol 39(1):27–31

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ et al (2019) Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 393:40–50

    Article  CAS  PubMed  Google Scholar 

  5. Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T et al (2019) Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 393:51–60

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Tata Memorial Centre, HBNI, Mumbai, India

    Monali Swain & JaiPrakash Agarwal

  2. Department of Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Kharghar, Navi Mumbai, 410210, India

    Tejpal Gupta

  3. Clinical Research Secretariat, ACTREC, Tata Memorial Centre, HBNI, Navi Mumbai, India

    Sadhana Kannan

Authors
  1. Monali Swain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tejpal Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sadhana Kannan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. JaiPrakash Agarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tejpal Gupta.

Ethics declarations

Conflict of interest

None of the authors have any conflicts to declare.

Research involving human participants

Not applicable as this is a comment on a recent article in the journal and does not involve research on human participants.

Informed consent

Not applicable, this is a comment on a recent article in the journal and does not involve research on human participants.

Institutional ethics committee approval

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Swain, M., Gupta, T., Kannan, S. et al. Cisplatin-based chemoradiotherapy trumps cetuximab-based bioradiotherapy in p16/HPV-positive oropharyngeal cancers. Eur Arch Otorhinolaryngol 276, 2111–2112 (2019). https://doi.org/10.1007/s00405-019-05441-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00405-019-05441-5

Search

Navigation